Who are Vortioxetine (Lu AA21004)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vortioxetine tablets, Trintellix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vortioxetine-lu-aa21004.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vortioxetine (Lu AA21004) — Competitive Intelligence Brief

Vortioxetine (Lu AA21004) (Vortioxetine (Lu AA21004)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin modulator and stimulator. Area: Psychiatry.

phase 3 Serotonin modulator and stimulator 5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Vortioxetine (Lu AA21004) (Vortioxetine (Lu AA21004)) — H. Lundbeck A/S. Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vortioxetine (Lu AA21004) TARGET	Vortioxetine (Lu AA21004)	H. Lundbeck A/S	phase 3	Serotonin modulator and stimulator	5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter
Vortioxetine tablets	Vortioxetine tablets	Takeda	phase 3	Serotonin modulator and stimulator	5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin modulator and stimulator class)

H. Lundbeck A/S · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vortioxetine (Lu AA21004) — Competitive Intelligence Brief. https://druglandscape.com/ci/vortioxetine-lu-aa21004. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab